^
    5d
    Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Sarclisa (isatuximab-irfc)
    5d
    To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus (clinicaltrials.gov)
    P2, N=120, Recruiting, Hangzhou Sumgen Biotech Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    TAK-079-3003: A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=150, Recruiting, Takeda | N=105 --> 150
    Enrollment change • Trial initiation date
    |
    mezagitamab (TAK-079)
    10d
    IMPEDE: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting | N=53 --> 28 | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Apr 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    pomalidomide • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab)
    13d
    Oncolytic bovine herpesvirus type 1 induces immune microenvironment remodeling and enhances treatment responses in multiple myeloma. (PubMed, Haematologica)
    Co-treatment of BoHV-1 with either bortezomib or lenalidomide increased anti-MM cytotoxicity. Finally, BoHV-1 upregulated CD38 on both MM cells and immune effectors, thereby increasing sensitivity to the anti-CD38 daratumumab. These findings establish BoHV-1 as a promising immunovirotherapy agent, effective as a single agent and in combination strategies, by coupling direct oncolysis with broad immune remodeling of the BM microenvironment.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    lenalidomide • bortezomib • Darzalex (daratumumab)
    13d
    Vitamin D receptor expression in germinal centre type diffuse large B-cell lymphoma cells is associated with vitamin D insensitivity. (PubMed, Endocr Oncol)
    CD38 is also activated by VitD3 treatment of human peripheral B cell lines, where VDR can bind to the CD38 locus, suggesting direct regulation. Combined VDR and cell-of-origin assessment may contribute to a greater understanding of vitamin D's role in mature B-cell lymphoma and its interplay with BCL6 and MYC.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL6 (B-cell CLL/lymphoma 6) • CD38 (CD38 Molecule) • VDR (Vitamin D Receptor)
    |
    Darzalex (daratumumab)
    13d
    EMN39: A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=1000, Recruiting, European Myeloma Network B.V.
    Trial initiation date
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Lynozyfic (linvoseltamab-gcpt)
    14d
    Multiple Myeloma and Mimicry: Gastrointestinal Tract Histologic Findings in Patients Following Chimeric Antigen Receptor T-cell Therapy and Anti-CD38 Monoclonal Antibodies. (PubMed, Mod Pathol)
    Our findings suggest that CAR-T cell therapy causes gastrointestinal injury characterized by epithelial cell apoptosis and intraepithelial lymphocytosis and predominantly affects crypts and glands in the deep mucosa. Recognizing this pattern may help pathologists suggest the presence of CAR-T cell therapy-induced injury in the appropriate clinical context.
    Journal
    |
    CD19 (CD19 Molecule)
    |
    Darzalex (daratumumab)
    20d
    Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=62, Not yet recruiting, Natalie Callander
    New P1/2 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 deletion
    |
    Xpovio (selinexor) • carfilzomib • dexamethasone injection • isatuximab subcutaneous (SAR650984 SC)
    21d
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P1, N=258, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    21d
    IFm2022-01: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, Nantes University Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Apr 2028
    Enrollment closed • Trial primary completion date • Minimal residual disease
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    22d
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection